Tixagevimab-cilgavimab for the prevention of COVID-19: real-world experience in patients with rheumatic diseases receiving rituximab
Authors' conclusion
TIX-CIL was well tolerated and effective in reducing the incidence of COVID-19 in the subsequent 3 months.
Study context
- Population
- Patients with rheumatic diseases receiving rituximab for ≥12 months
- Participants
- 330 patients
- Exposure
- Tixagevimab-cilgavimab (TIX-CIL) vs no TIX-CIL
- TIX-CILn = 142
- Refused TIX-CILn = 188reference
- Outcome
- SARS-CoV2 infection (COVID-19)
- Follow-up
- 6 months
Methodological detailsreal-world, multivariate analyses
- Real-world
- Multivariate analyses
Main finding
As reported in the abstract
COVID-19 incidence · month 6
P = 0.42
Observational data: associations, not effects.
Further findings
COVID-19 · month 3
P = 0.003
| Outcome | OR (CI) | |
|---|---|---|
| COVID-19 · month 3Logistic regression; independent protective factor | 0.35 (0.17–0.73) | |
| 0.10.31310Odds ratio (log scale) |
Severe COVID-19 · month 6
- Severe COVID-19 in 11 (3.3%) patients overall; no difference between the two groups
Safety
Adverse events to TIX-CIL
- Exclusively mild and self-limiting; most common musculoskeletal pain, headache and dizziness
Original publication
Tixagevimab-cilgavimab for the prevention of COVID-19: real-world experience in patients with rheumatic diseases receiving rituximab. Clin Exp Rheumatol. Published 22 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →